Core Insights - ICON plc is under investigation following an internal accounting probe that revealed potential revenue overstatements for fiscal years 2023 and 2024, estimated at up to 2% each year [1] - The company has delayed the release of its fourth-quarter and full-year 2025 financial results due to this investigation [1] Company Overview - ICON plc is one of the largest contract research organizations (CROs) globally, providing outsourced drug development and clinical trial management services to pharmaceutical and biotechnology companies [1] - The CRO industry relies on long-term service contracts, making accurate revenue recognition critical [1] Financial Impact - An overstatement of up to 2% on annual revenue, given ICON's reported full-year revenue exceeding $8 billion, could represent a discrepancy of approximately $160 million per year [1] - This discrepancy could materially affect earnings per share, operating margins, and year-over-year growth rates [1] Recent Financial Performance - In the third quarter of 2025, the company reported revenue of $2.043 billion, reflecting a year-on-year increase of 0.6% [1] - The previous year's comparison figures for this growth claim are now under review due to the ongoing investigation [1] Market Reaction - Following the February 12, 2026 disclosure, ICON plc's shares declined approximately 40%, resulting in the loss of billions in market capitalization [1] - The company had repurchased $750 million of its own shares in the first three quarters of 2025 and authorized an additional $1 billion repurchase program in the second quarter, which was presented against a backdrop of a "very strong" financial position [1]